Moreover, in specific leukemia subtypes characterized by the presence of mutations or rearrangements of genes such as FLT-3 or BCR-ABL resulting in high expression of constitutively activated oncoproteins, the association of HSP90 inhibitors and targeted drugs is highly effective in vitro [35, 36]. This evidence concerns the gene ABL1 and leukemia.